Literature DB >> 24758500

[WHO classification of tumours of soft tissue and bone 2013: the main changes compared to the 3rd edition].

Iva Zambo, Karel Veselý.   

Abstract

In early 2013, the new classification of tumours of soft tissue and bones was released. This edition belongs to the fourth series of so-called Blue Books published under the auspices of the World Health Organisation (WHO). The current classification follows the previous third edition, from which it differs in several aspects. The vast majority of changes are related to the soft tissue tumour section, which was enriched with three new chapters, some entities or terms were removed, new diagnoses were introduced, and several tumours were reallocated to other categories. Albeit to a lesser extent, similar changes have occurred also in the classification of bone tumours. Compared to the previous edition, more detailed molecular and cytogenetic data were incorporated in the current issue. The rapidly increasing knowledge of the genetics of mesenchymal tumours allows us to make more accurate diagnoses as well as to better understand of the pathogenesis of these lesions. However, abundant molecular and cytogenetic data highlight an increasing problem of growing numbers of genetic overlaps even among quite different tumours. The coexistence of several grading systems of soft tissue tumours is another controversial issue mentioned in the recent WHO classification. The main advantages and limitations of the two most widely used grading systems are also discussed.

Entities:  

Mesh:

Year:  2014        PMID: 24758500

Source DB:  PubMed          Journal:  Cesk Patol        ISSN: 1210-7875


  56 in total

1.  A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers.

Authors:  Michael J Bollong; Mika Pietilä; Aaron D Pearson; Tapasree Roy Sarkar; Insha Ahmad; Rama Soundararajan; Costas A Lyssiotis; Sendurai A Mani; Peter G Schultz; Luke L Lairson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

Review 2.  Capitate Chondroblastoma: A Case Report and Review of the Literature.

Authors:  Ali Izadpanah; Riyam T Zreik; Thomas Shives; Sanjeev Kakar
Journal:  Hand (N Y)       Date:  2016-07-08

3.  [Report of the Working Group on Osseous, Joint and Soft Tissue Pathology : DGP conference on 22nd June 2017, Erlangen].

Authors:  S Scheil-Bertram; V Krenn
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

4.  A prospective study on predicting local recurrence of giant cell tumour of bone by evaluating preoperative imaging features of the tumour around the knee joint.

Authors:  Yifeng He; Jun Wang; Ji Zhang; Fei Yuan; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

Review 5.  [Morphological spectrum of USP6 rearranged lesions].

Authors:  G Mechtersheimer; M Werner
Journal:  Pathologe       Date:  2018-03       Impact factor: 1.011

6.  Oncolytic adenovirus Ad11 enhances the chemotherapy effect of cisplatin on osteosarcoma cells by inhibiting autophagy.

Authors:  Bin Zhang; Yan Zhang; Rongzhen Li; Jiazhen Li; Xinchang Lu; Yi Zhang
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

7.  Superficial CD34-positive fibroblastic tumor: report of two cases and review of literature.

Authors:  Xu Mao; Ying-Ying Sun; Ming-Liang Deng; Tao Ma; Lan Yu
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

8.  Intracranial arterial dolichoectasia and skull damage in a girl with Jaffe-Campanacci syndrome: a case report.

Authors:  Yong Han; Hangzhou Wang
Journal:  Childs Nerv Syst       Date:  2019-02-05       Impact factor: 1.475

Review 9.  Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Authors:  Xiaolei Ren; Chao Tu; Zhenchu Tang; Ruofei Ma; Zhihong Li
Journal:  Oncol Lett       Date:  2018-03-22       Impact factor: 2.967

Review 10.  Epithelioid hemangioma of bone: a report of two special cases and a literature review.

Authors:  Qin Zhou; Liangji Lu; YanBiao Fu; KeWei Xiang; Leiming Xu
Journal:  Skeletal Radiol       Date:  2016-09-22       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.